PMID- 14703068
OWN - NLM
STAT- MEDLINE
DCOM- 20040330
LR  - 20181130
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 82
IP  - 3
DP  - 2003 Dec
TI  - Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression 
      of HER2/neu in patients with breast cancer.
PG  - 207-13
AB  - BACKGROUND: In primary breast cancer, the expression levels of biological markers 
      relevant to the progression of the disease may be altered by administration of 
      anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is 
      increasingly used in advanced breast cancer, our purpose was to assess the 
      influence of this neoadjuvant chemotherapy on the expression of the growth factor 
      receptor HER2/neu. PATIENTS AND METHODS: We investigated changes of HER2/neu 
      status by immunohistochemistry (IHC) and applied additional fluorescence in situ 
      hybridization (FISH) in patients with potential modulation of HER2/neu status 
      after administration of neoadjuvant chemotherapy with docetaxel and epirubicin in 
      97 breast cancer patients. The influence of neoadjuvant chemotherapy on HER2/neu 
      expression was calculated by correlation of HER2/neu status before and after 
      chemotherapy. RESULTS: The accuracy of HER2/neu assessment before and after 
      neoadjuvant chemotherapy by IHC combined with FISH analysis in selected cases was 
      100%. The evaluation of HER2/neu status in these patients by IHC alone yielded 
      accuracy of 93%. Neoadjuvant chemotherapy with epirubicin and docetaxel caused no 
      significant modulation of HER2/neu status (p = 0.66). DISCUSSION: The 
      administration of epirubicin and docetaxel in the neoadjuvant setting is not 
      associated with significant changes of HER2/neu status in primary breast cancer. 
      As a consequence, drug resistance or sensitivity is not induced by modulation of 
      HER2/neu expression. Moreover, the time of assessment of the HER2/neu status is 
      not a critical factor under neoadjuvant therapy with epirubicin and docetaxel.
FAU - Taucher, Susanne
AU  - Taucher S
AD  - Department of Surgery, Vienna University Medical School, Vienna, Austria. 
      susanne.taucher@univie.ac.at
FAU - Rudas, Margaretha
AU  - Rudas M
FAU - Mader, Robert M
AU  - Mader RM
FAU - Gnant, Michael
AU  - Gnant M
FAU - Sporn, Emanuel
AU  - Sporn E
FAU - Dubsky, Peter
AU  - Dubsky P
FAU - Roka, Sebastian
AU  - Roka S
FAU - Bachleitner, Thomas
AU  - Bachleitner T
FAU - Fitzal, Florian
AU  - Fitzal F
FAU - Kandioler, Daniela
AU  - Kandioler D
FAU - Wenzel, Catharina
AU  - Wenzel C
FAU - Steger, Gunther G
AU  - Steger GG
FAU - Mittlbock, Martina
AU  - Mittlbock M
FAU - Jakesz, Raimund
AU  - Jakesz R
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - 3Z8479ZZ5X (Epirubicin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*drug therapy/genetics/pathology
MH  - Docetaxel
MH  - Epirubicin/administration & dosage
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Taxoids/administration & dosage
EDAT- 2004/01/02 05:00
MHDA- 2004/03/31 05:00
CRDT- 2004/01/02 05:00
PHST- 2004/01/02 05:00 [pubmed]
PHST- 2004/03/31 05:00 [medline]
PHST- 2004/01/02 05:00 [entrez]
AID - 10.1023/B:BREA.0000004378.15859.51 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2003 Dec;82(3):207-13. doi: 
      10.1023/B:BREA.0000004378.15859.51.